Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina

Laboratory Investigation

Volumn 75, Issue 3, 1996, Pages 325-338

  Hammes, Hans Peter ^a   Weiss, Antje ^a   Hess, Sibylle ^b,c   Araki, Norie ^c   Horiuchi, Seikoh ^b,c   Brownlee, Michael ^d   Preissner, Klaus T ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b KERCKHOFF HEART CENTER   (Germany)

^c University School of Medicine   (Japan)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; COLLAGEN TYPE 1; GLYCOSAMINOGLYCAN; GLYCOSYLATED PROTEIN; LYSINE; OSTEONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEOGLYCAN; PROTEOHEPARAN SULFATE; TENASCIN; VITRONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; RAT; RETINA BLOOD VESSEL; RETINA CAPILLARY; STREPTOZOCIN DIABETES;

ANIMALS; CELL ADHESION; DIABETES MELLITUS, EXPERIMENTAL; EXTRACELLULAR MATRIX; GLYCOSYLATION END PRODUCTS, ADVANCED; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROTEOGLYCANS; RATS; RATS, WISTAR; REFERENCE VALUES; RETINA; TISSUE DISTRIBUTION; VITRONECTIN;

EID: 0029830984     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Anderson SS, Tsilibary EC, and Charonis AS (1993). Nonenzymatic glycosylation-induced modifications of intact bovine kidney tubular basement membrane. J Clin Invest 92:3045-3052.
2. Araki N, Ueno N, Chakraharti B, and Morino Y (1992). Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J Biol Chem 267:10211-10214.
3. Brownlee M (1994). Glycation and diabetic complications. Diabetes 43:836-841.
4. Brownlee M (1992). Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15:1835-1843.
5. Brownlee M, Cerami A, and Vlassara H (1988). Advanced glycation end products in tissue and the biochemical basis of complications. N Engl J Med 318:1315-1320.
6. Brownlee M, Vlassara H, and Cerami A (1984). Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Diabetes 33:532-535.
7. Brunner G and Preissner KT (1994). Pericellular enyzmatic hydrolysis: Implications for the regulation of cell proliferation in the vessel wall and the bone marrow. Blood Coagul Fibrinol 5:625-639.
8. Casaroli Marano RP, Preissner KT, and Vilaro S (1995). Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy. Exp Eye Res 60:5-17.
9. Ceriello A, Marchi E, Barbanti M, Milani MR, Giugliano D, Quatraro A, and Lefebvre P (1990). Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity. Diabetes 33:205-207.
10. Chain D, Kreizman T, Shapira H, and Shaltiel S (1991). Plasmin cleavage of vitronectin: Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. FEBS Lett 285:251-256.
11. Charonis AS, Reger LA, Dege JE, Kouzi-Koliakos K, Furcht LT, Wohlhueter RM, and Tsilibary EC (1990). Laminin alterations after in vitro nonenzymatic glucosylation. Diabetes 39:807-814.
12. Ciambrone GJ and McKeown-Longo PJ (1990). Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells. J Cell Biol 111:2183-2195.
13. de Boer HC, Preissner KT, Bouma BN, and de Groot PG (1992). Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem 267:2264-2268.
14. de Boer HC, Preissner KT, Bouma BN, and de Groot PG (1995). Internalization of vitronectin-thrombin-antithrombin complex by endothelial cells leads to deposition of the complex into the subendothelial matrix. J Biol Chem 270:30733-30740.
15. Eble AS, Thorpe SR, and Baynes JW (1983). Nonenzymatic glucosylation and glucose-dependent cross-linking of proteins. J Biol Chem 258:9506-9512.
16. Federoff HJ, Lawrence D, Brownlee M, and Charonis AS (1993). Non enzymatic glycosylation of laminin and the laminin peptide CIKVAVS inhibits neurite outgrowth. Diabetes 42:509-513.
17. Felding-Habermann B and Cheresh DA (1993). Vitronectin and its receptors. Curr Opin Cell Biol 5:864-868.
18. Giardino I, Edelstein D, and Brownlee M (1994). Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. J Clin Invest 94:110-117.
19. Grulich-Henn J, Preissner KT, and Müller-Berghaus G (1990). Heparin stimulates fibrinolysis in mesothelial cells by selective induction of tissue-plasminogen activator but not plasminogen activator inhibitor-1 synthesis. Thromb Haemostas 64:420-425.
20. Haitoglou CS, Tsilibary EC, Brownlee M, and Charonis AS (1992). Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 267:12404-12407.
21. Hammes HP, Martin S, Federlin K, Geisen K, and Brownlee M (1991). Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555-11558.
22. Horiuchi S, Araki N, and Morino Y (1991). Immunochemical approach to characterize advanced glycation end products of the maillard reaction: Evidence for the presence of a common structure. J Biol Chem 266:7329-7332.
23. Ibanez CF, Hallböök F, Söderström S, Ebendahl T, and Person H (1991). Biological and immunological properties of recombinant human, rat, and chicken nerve growth factors: A comparative study. J Neurochem 57:1033-1041.
24. Kost C, Stüber W, Ehrlich H, Pannekoek H, and Preissner KT (1992). Mapping of binding sites for heparin, plasminogen activator inhibitor-1 and plasminogen to vitronectin's heparin binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 267:12098-12105.
25. Laemmli UK (1970). Cleavage of structure proteins during assembly of the head bacteriophage T4. Nature 227:680-685.
26. Lane DA, Flynn AM, Pejler G, Lindahl U, Choay J, and Preissner KT (1987). Structural requirements for the neutralization of heparin-like saccharides by complement S protein/ vitronectin. J Biol Chem 262:16343-16349.
27. Mimuro J and Loskutoff DJ (1989). Purification of a protein from bovine plasma that binds to type-1 plasminogen-activator inhibitor and prevents its interaction with extracellular matrix: Evidence that the protein is vitronectin. J Biol Chem 264:936-939.
28. Miskin R, Axelrod JH, Griep AE, Lee E, Belin D, Vassalli JD, and Westphal H (1990). Human and murine urokinase cDNAs linked to the murine A-crystallin promotor exhibit lens and non-lens expression in transgenic mice. Eur J Biochem 190:31-38.
29. Preissner KT (1991). Structure and biological role of vitronectin. Annu Rev Cell Biol 7:275-310.
30. Preissner KT, Anders E, Grulich-Henn J, and Müller-Berghaus G (1988). Attachment of cultured human endothelial cells is promoted by specific association with S protein (vitronectin) as well as with the ternary S protein-thrombin-antithrombin III complex. Blood 71:1581-1589.
31. Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, Pannekoek H, and Müller-Berghaus G (1990). Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 265:18490-18498.
32. Preissner KT, Holzhüter S, Justus C, and Müller-Berghaus G (1989). Identification and partial characterization of platelet vitronectin: Evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 74:1989-1996.
33. Preissner KT and Müller-Berghaus G (1987). Neutralisation and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin binding domain of S protein/vitronectin. J Biol Chem 262:12247-12253.
34. Preissner KT, Wassmuth R, and Müller-Berghaus G (1985). Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J 231:349-355.
35. Ruderman N, Williamson J, and Brownlee M (1992). Glucose and diabetic vascular disease. FASEB J 6:2905-2914.
36. Ruoslahti E and Yamaguchi Y (1991). Proteoglycans as modulators of growth factor activities. Cell 64:867-869.
37. Sage EH and Bornstein P (1991). Extracellular proteins that modulate cell-matrix interactions: Sparc, tenascin, and thrombospondin. J Biol Chem 266:14831-14834.
38. Scott DJ, Dollery CT, and Hill DW (1964). Fluorescein studies of diabetic retinopathy. Br Med J 1:1-811.
39. Sensi M, Tanzi P, Bruno RM, Mancuso M, and Andriani D (1986). Human glomerular basement membrane: Altered binding characteristics following in vitro non-enzymatic glycosylation. Ann N Y Acad Sci 488:549-552.
40. Stockmann A, Hess S, Declerck P, Timpl R, and Preissner KT (1993). Multimeric vitronectin: Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem 268:22874-22882.
41. Tomasini BR and Mosher DF (1990). Vitronectin. Prog Hemostas Thromb 10:269-305.
42. Towbin H, Staehelin T, and Gordon J (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354.
43. Villanueva GB and Allen N (1988). Demonstration of altered antithrombin III activity due to nonenzymatic glycosylation at glucose concentration expected to be encountered in severely diabetic patients. Diabetes 37:1103-1107.
44. Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, and Fuks Z (1990). Extracellular matrix-resident growth factors and enzymes: Possible involvement in tumor metastasis and angiogenesis. Cancer Metastas Rev 9:203-226.
45. Yatohgo T, Izumi M, Kashiwagi H, and Hayashi M (1988). Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct 13:281-292.
46. Yayon A, Klagsbrun M, Esko JD, Leder P, and Ornitz DM (1991). Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841-848.